Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

1.1K
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.1K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

527
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
527
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

2.2K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
2.2K
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

863
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
863
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

524
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
524
Pathophysiology of Peptic Ulcer Disease: Injurious Factors01:22

Pathophysiology of Peptic Ulcer Disease: Injurious Factors

1.2K
Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Genetics and Epigenetics of Primary Biliary Cholangitis.

Clinics in liver disease·2018
Same author

Development of a new tubal recanalization method using the combination of hysteroscope and laparoscope in the treatment of obstructed fallopian tubes.

Gynecology and minimally invasive therapy·2018
Same author

Illuminating the optimal anastomosis site with optical coherence tomography in coronary artery bypass surgery.

Journal of cardiac surgery·2018
Same author

IgG4-Related Sclerosing Cholangitis and Primary Sclerosing Cholangitis.

Gut and liver·2018
Same author

[Autoimmune liver diseases -issues to be solved in Japan].

Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology·2018
Same author

Effects of uric acid on vascular endothelial function from bedside to bench.

Hypertension research : official journal of the Japanese Society of Hypertension·2018

Related Experiment Video

Updated: Feb 8, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

1.6K

Ulcerative Colitis with and without Primary Sclerosing Cholangitis: Two Different Diseases?

Atsushi Tanaka1, Joachim C Mertens2

  • 1Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan.

Inflammatory Intestinal Diseases
|June 21, 2018
PubMed
Summary

Primary sclerosing cholangitis (PSC) is linked to inflammatory bowel diseases (IBD), particularly ulcerative colitis (UC). Gut pathology, including microbiota and immune responses, may differ in UC patients with PSC compared to typical UC.

Keywords:
Primary sclerosing cholangitisUlcerative colitis

More Related Videos

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
09:04

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat

Published on: February 27, 2014

49.0K
Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
09:11

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model

Published on: February 14, 2021

10.6K

Related Experiment Videos

Last Updated: Feb 8, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

1.6K
DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
09:04

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat

Published on: February 27, 2014

49.0K
Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
09:11

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model

Published on: February 14, 2021

10.6K

Area of Science:

  • Hepatology
  • Gastroenterology
  • Immunology

Background:

  • Primary sclerosing cholangitis (PSC) is a chronic liver disease often associated with inflammatory bowel diseases (IBD), especially ulcerative colitis (UC).
  • Prevalence of PSC in UC patients varies globally, with notable differences observed between Eastern and Western populations.
  • UC patients with PSC exhibit distinct clinical features, such as rectal sparing and right-sided colonic inflammation.

Purpose of the Study:

  • To investigate the potential differences in the pathogenesis of PSC in ulcerative colitis (UC) patients between Eastern and Western populations.
  • To explore the role of gut pathology, including microbiota and mucosal immune responses, in the development of PSC in UC.

Main Methods:

  • This study is a review and analysis of existing literature and registry data on PSC and IBD.
  • Comparative analysis of clinical features and epidemiological data of PSC in UC patients from different geographical regions.
  • Discussion of the implications of genetic studies, including genome-wide association studies (GWAS), in understanding PSC pathogenesis.

Main Results:

  • PSC is a significant complication of IBD, with prevalence rates varying across different regions.
  • Clinical presentations of UC in patients with PSC differ from those without PSC.
  • The link between atypical IBD and PSC suggests a role for gut microbiota and mucosal immunity in its pathogenesis.

Conclusions:

  • The pathogenesis of PSC in UC likely involves gut pathology, differing from typical UC.
  • Genetic studies, particularly GWAS, are crucial for elucidating geographical differences in PSC and its association with IBD.
  • Further research is warranted in Eastern populations to address the 'East versus West' question in PSC.